Primary Myelofibrosis Terminated Phase 2 Trials for Nivolumab (DB09035)
Also known as: Myelofibrosis, Primary / Osteomyelofibrosis / Chronic idiopathic myelofibrosis
| Indication | Status | Phase |
|---|---|---|
| DBCOND0001581 (Primary Myelofibrosis) | Terminated | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | Treatment |